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Background: An annual oral glucose tolerance test (OGTT) has become part of standard care in cystic ﬁbrosis (CF) to screen for CF-related
diabetes (CFRD). The objective of this study was to determine predictors for future CFRD derived from an OGTT.
Methods: Data were collected from 2001 to 2009 during a longitudinal prospective study on “Early Diagnosis of Diabetes Mellitus in CF Patients,
trial number NCT00662714”. The 1093 patients included in the analysis had at least two valid OGTTs each and no CFRD at the ﬁrst glucose
challenge. Normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and CFRD were deﬁned using
WHO criteria. In a subsample of 521 patients, the NGT group was further divided into patients with a 1-hour glucose level N11.1 mmol/l
(indeterminate glucose tolerance— INDET) and those with a lower level (no-INDET). Logistic regression analysis was used to identify predictors
from the ﬁrst OGTT for future diabetes.
Results: Compared with NGT (n = 838), IFG (n = 70; odds ratio [OR], 95% conﬁdence interval: 2.92, 1.60–5.33) and IGT without IFG (n = 155,
OR 2.37, 1.48–3.79) were both signiﬁcant and independent risk factors for future CFRD. Patients with IGT and IFG (n = 30) had the highest risk
(OR 5.30, 2.32–12.10). In the subsample analysis, INDET (n = 116) was associated with a signiﬁcantly increased risk for future CFRD compared
with no-INDET (n = 269; OR 2.81, 1.43–5.51).
Conclusions: In this large study, IFT, IGT, and INDET were all predictors of future CFRD. The OGTT in patients with CF should include a 1-hour
post-challenge value.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Cystic ﬁbrosis-related diabetes; Oral glucose tolerance test1. Introduction
With increasing survival of patients with cystic fibrosis
(CF), cystic fibrosis-related diabetes (CFRD) has become the
most common co-morbidity in CF [1]. CFRD is currently
present in 2% of children, 19% of adolescents and 40–50% of
adults [2]. Untreated CFRD is associated with a significant
decline in pulmonary function, nutritional status and an up to
6-fold increase in mortality [1–3].⁎ Corresponding author. Tel.: +49 931 201 27728; fax: +49 931 201 27798.
E-mail address: Schmid_K@klinik.uni-wuerzburg.de (K. Schmid).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.06.001Irrespective of the mechanisms underlying CFRD, it's early
detection is of vital importance. Using HbA1c and/or symptoms
as the only means of screening for CFRD, many patients would
be missed [3]. Therefore it is currently recommended to perform
an oral glucose tolerance test (OGTT) on an annual basis in
all non-diabetic patients who are 10 years of age or older [3,4].
According to the World Health Organization (WHO), the
baseline (fasting) glucose level and the level two hours after a
standardized oral glucose challenge are used to characterize
glucose tolerance: Normal Glucose Tolerance (NGT), Impaired
Fasting Glycemia (IFG), Impaired Glucose Tolerance (IGT) and
Diabetes Mellitus (DM) [5]. For the general population, the
WHO considers IFG and IGT as two independent risk indicatorsby Elsevier B.V. All rights reserved.
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glucose regulation, one effective in the fasting state and one
post-prandial [5].
Also in CF, IFG [6,7] and IGT [8–10] have both been
associated with an increased risk for future CFRD, even though
the former association has been challenged [11]. It has been
suggested that, in CF, IFG reflects an extensive hepatic glucose
production while IGT may be based on insufficient first-phase
and peak insulin secretion as well as insulin resistance [11,12].
Recently, a high blood glucose level one hour after a glucose
load with normal fasting glucose and a normal 2-hour post-
challenge glucose (referred to as indeterminate glycemia —
INDET) has been associated with a poor pulmonary function in
CF [13]. However, the relevance of INDET with respect to the
development of future CFRD has only been assessed in a small
group of prepubertal children [10]. Nevertheless, assessing also
the glucose level one hour after a standardized glucose challenge
has been recommended when testing people with CF [13] and
respective data have been included in a recent classification of
glucose tolerance in CF [4].
Furthermore, the relative importance of the different risk
indicators to predict CFRD is unclear. Therefore, the objective
of this study was to identify predictors for future CFRD based on
a standardized OGTT in a large cohort of patients followed
prospectively. We also intended to develop a model to predict the
occurrence of CFRD based on all independent risk indicators
identified. We hypothesized that IFG, IGT, and INDET would all
be independent risk indicators for future CFRD.
2. Patients and methods
This study is based on data collected during an ongoing
longitudinal prospective study on the incidence of diabetes
mellitus in CF (Early Diagnosis of Diabetes Mellitus in CF
Patients; Trial Nr. NCT00662714). Briefly, 43 participating
centers from Germany and Austria performed standardized
OGTTs following the WHO guidelines in patients with CF,
aged 10 years or older, at least on an annual basis [5]. All data
entered in the database from January 2001 to May 2009 were
considered for analysis. The study has been approved by the local
ethics committees of all participating centers. Written informed
consent was obtained from the patients or guardians, if applicable.
2.1. Subjects
Data from 1790 patients were available in the database.
Inclusion criteria were: diagnosis of CF and age of 10 years or
older. All patients were clinically stable at the time of the OGTT,
with no recent pulmonary exacerbation and no symptoms
suggesting acute infection. Exclusion criteria of the study were:
patients with only one valid OGTT during the study period,
patients who were already diagnosed with CFRD before or at
first OGTT and patients with pregnancy, steroid therapy, lung
transplantation, hypocaloric nutrition 3 days before OGTT-
testing, supplemental enteral feeds e.g. gastrostomy/nasogastric
tube or exceptional stress (for instance surgery). Inclusion and
exclusion criteria were checked prior to each OGTT by the CFcenter's physician. In total, data including fasting glucose and
blood glucose levels determined two hours after the glucose
challenge in 1093 patients were analyzed. In 521 patients of the
1093 patients, an additional blood glucose value one hour after
the glucose load was available.
2.2. Oral glucose tolerance testing and interpretation
TheOGTTs were performed followingWHOguidelines [5], as
described previously [6]. Briefly, a first blood sample was drawn
in the morning after an overnight fast to determine the fasting
glucose level. Then, a standardized oral challenge was performed
with 1.75 g glucose per kg body weight (maximum 75 g).
A second blood sample was collected 2 h after the glucose
challenge.
OGTT results were categorized following WHO recommen-
dations [5]. In addition to the standard WHO classification, the
group of patients with IGT was divided in those without IFG
and those with IFG. This additional division was based on two
considerations: 1) one objective of our study was to determine
the relative importance of different risk indicators for future
CFRD. For this purpose, a clear distinction between IFG and
IGT (without IFG) was required. 2) In contrast to the WHO, the
American Diabetes Association (ADA) defines IGT as a state
with normal fasting glucose but elevated two hour glucose levels
[14]. This definition is reflected in the ‘IGT without IFG’ group
in our study and, thus, allows direct comparisons between risk
indicators based on WHO and ADA definitions.
In the subsample of 521 patients with an additional glucose
level one hour after the glucose load, patients with normal
glucose tolerance were divided into those with a 1-hour plasma
glucose value of ≥11.1 mmol/l (≥200 mg/dl, indeterminate
glycemia = INDET) and those with a lower value (no-INDET)
[10]. The definitions of OGTT categories used in the current
study are summarized in Table 1.
2.3. Statistical analysis
Annual OGTT data were available for most subjects. However,
only the first and the final OGTT results were included in the
analysis. Data included age, gender and BMI at first, as well as
time interval between first and final OGTT. The groups of patients
categorized by glycemic control at first OGTT (NGT, IFG,
INDET, IGT without IFG and IGT with IFG) were compared in a
multivariable regression model. Differences between the groups
regarding the incidence of diabetes mellitus at the last available
test were analyzed using Chi-square statistics. Analyzing the
incidence of CFRD at the last OGTT for patients with IFG, IGT
without IFG, or IGT with IFG in the first OGTT, the group with
NGTwas taken as reference group. Likewise, Chi-square statistics
was employed to compare the incidence of CFRD in the last
OGTT between patients with INDET and those with normal
glucose tolerance and no INDET.
Logistic regression models were fitted with CFRD at the last
OGTT (yes/no) as dependent variable. Independent predictors
included in the model were age (years), gender, BMI (standard
deviation score), and time between first and last OGTT (years).
Table 1
Definition of OGTT categories.
OGTT category Fasting plasma glucose level a Plasma glucose level 2-h after the challenge a Sub-category
Venous and capillary Venous Capillary Venous and capillary
NGT b6.1 mmol/l (b110 mg/dl) b7.8 mmol/l (b140 mg/dl) b8.9 mmol/l (b160 mg/dl) No INDET
(1-hour plasma glucose value
b11.1 mmol/l; b200 mg/dl)
INDET
(1-hour plasma glucose value
≥11.1 mmol/l; ≥200 mg/dl)
IFG ≥6.1 and b7.0 mmol/l
(≥110 and b126 mg/dl)
b7.8 mmol/l (b140 mg/dl) b8.9 mmol/l (b160 mg/dl)
IGT without IFG b6.1 mmol/l (b110 mg/dl) ≥7.8 and b11.1 mmol/l
(≥140 and b200 mg/dl)
≥8.9 and b12.2 mmol/l
(≥160 and b220 mg/dl)
IGT with IFG ≥6.1 and b7.0 mmol/l
(≥110 and b126 mg/dl)
≥7.8 and b11.1 mmol/l
(≥140 and b200 mg/dl)
≥8.9 and b12.2 mmol/l
(≥160 and b220 mg/dl)
CFRD ≥7.0 mmol/l (≥126 mg/dl) b ≥11.1 mmol/l (≥200 mg/dl) b ≥12.2 mmol/l (≥ 220 mg/dl) b
NGT, normal glucose tolerance; INDET, indeterminate glycemia; IFG, impaired fasting glycemia; IGT, impaired glucose tolerance; CFRD, cystic fibrosis-related
diabetes.
a For whole blood glucose samples, cut-offs were 15% lower than corresponding plasma values according to WHO guidelines [5].
b For the diagnosis of CFRD, either the fasting glucose or the 2-hour glucose level criterion needs to be fulﬁlled.
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first OGTT (yes/no), and IGT with IFG at first OGTT (yes/no)
were included as predictors. Relative risk was calculated using
the NGT group as reference group. In a separate logistic
regression analysis, using only patients in whom a glucose
value was available 1 hour after the challenge, INDET (yes/no)
was also included, taking the no-INDET group as reference.
All analyses were performed using the SAS 9.2 software
package. Statistical significance was assumed at p b 0.05.3. Results
The mean age of the 1093 patients was 18.4 ± 8.7 years at
their first OGTT. The respective age of the 521 patients
contributing data for INDET analysis was 17.9 ± 8.5 years.
Average time between first and last tests was 3.6 ± 2.1 and
3.7 ± 2.1 years, respectively. There was no significant differ-
ence between patients with and those without CFRD at the end
of the study period with respect to age, gender, BMI-SDS, andTable 2
Change in glycemic control determined by oral glucose tolerance testing over 3.6 ± 2
were classified according to WHO guidelines.
NGT IF
Glucose response at the first OGTT NGT n = 595
(71.0%)
n =
(5.5
IFG n = 36
(51.4%)
n =
(8.6
IGT without IFG n = 77
(49.7%)
n =
(3.2
IGT with IFG n = 9
(30.0%)
n =
(10.
Total n = 717
(65.6%)
n =
(5.5time interval between first and last OGTT in the entire study
population and the subsample with 1-hour post-challenge data.
Table 2 summarizes the distribution of glucose response
patterns to the first and to the final oral glucose challenge
according to WHO guidelines. The incidence of CFRD at the
last OGTT was about twice in the IFG and IGT without IFG
groups compared with the NGT group. The highest rate of
CFRD was seen in the group with both, IFG and IGT, at the
first OGTT. Chi-square statistics showed that the incidence of
CFRD was significantly higher in the IFG (p = 0.0005), IGT
without IFG (p = 0.0007), and the IGT with IFG (p = 0.00009)
groups compared with the NGT group.
Table 3 displays the results of the logistic regression analysis
describing the value of IFG, IGT without IFG, and IGT with IFG
to predict future CFRD. Both, IFG and IGT, are independent risk
indicators.
In the subsample of 521 patients with available blood glucose
values one hour after the glucose load at baseline, the incidence of
CRFD at the last OGTTwas significantly increased in the INDET
group over the no-INDET group (Chi2; p = 0.002) (Table 4). As.1 years in 1093 patients with CF and no CF-related diabetes at first test. Patients
Glucose response at the last OGTT
G IGT without IFG IGT with IFG CFRD Total
46
%)
n = 99
(11.8%)
n = 11
(1.3%)
n = 87
(10.4%)
n = 838
(76.7%)
6
%)
n = 10
(14.3%)
n = 1
(1.4%)
n = 17
(24.3%)
n = 70
(6.4%)
5
%)
n = 41
(26.5%)
n = 1
(0.7%)
n = 31
(20.0%)
n = 155
(14.2%)
3
0%)
n = 5
(16.7%)
n = 3
(10.0%)
n = 10
(33.3%)
n = 30
(2.7%)
60
%)
n = 155
(14.2%)
n = 16
(1.5%)
n = 145
(13.3%)
n = 1093
(100%)
Table 3
Logistic regression analysis to predict future CFRD by oral glucose tolerance
testing in 1093 patients with CF and no CF-related diabetes. Patients were
classified according to WHO guidelines.
Glucose response at
the first OGTT
Incidence of CFRD at
the last OGTT
Logistic regression odds
ratio (95% CI)
NGT n = 838
(76.7%)
n = 87
(10.4%)
Reference group
IFG n = 70
(6.4%)
n = 17
(24.3%)
2.92 (1.60–5.33)
n = 908
IGT without IFG n = 155
(14.2%)
n = 31
(20.0%)
2.37 (1.48–3.79)
n = 993
IGT with IFG n = 30
(2.7%)
n = 10
(33.3%)
5.30 (2.32–12.10)
n = 868
The model was adjusted for age at first OGTT, gender, BMI standard deviation
score and time between first and last test. None of these potential confounders
had a significant impact on the incidence of CFRD at the last OGTT.
Table 5
Logistic regression analysis to predict future CFRD by oral glucose tolerance
testing in 521 patients with CF and no CF-related diabetes. Patients were
classified according to WHO guidelines. Patients with NGT were further
divided into those without INDET and those with INDET.
Glucose response at
the first OGTT
Incidence of CFRD at
the last OGTT
Logistic regression odds
ratio (95% CI)
NGT, no INDET n = 269
(51.6%)
n = 19
(7.1%)
Reference group
NGT, INDET n = 116
(22.3%)
n = 20
(17.2%)
2.81 (1.43–5.51)
n = 385
IFG n = 44
(8.5%)
n = 11
(25.0%)
4.76 (2.05–11.05)
n = 313
IGT without IFG n = 76
(14.6%)
n = 17
(22.4%)
4.07 (1.95–8.47)
n = 345
IGT with IFG n = 16
(3.1%)
n = 7
(43.8%)
11.34 (3.67–35.03)
n = 285
The model was adjusted for age at first OGTT, gender, BMI standard deviation
score and time between first and last test. None of these potential confounders
had a significant impact on the incidence of diabetes at the last OGTT.
83K. Schmid et al. / Journal of Cystic Fibrosis 13 (2014) 80–85for the whole sample, IFG (p = b0.001), IGT without IFG
(p = b0.001), and IGT with IFG (p = b0.001) were also
associated with an increased risk for CFRD (Table 4).
Table 5 displays the results of the logistic regression analysis
describing the values of INDET, IFG, IGT without IFG, and IGT
with IFG to predict future CFRD compared to the no-INDET
group. Taking the no-INDET NGT group as reference, IFG and
IGT carried a higher relative risk to develop CFRD (Table 5)
compared to the analysis relating this risk to the NGT group as a
whole (Table 3).
The American Diabetes Association (ADA) recommends a
lower cut-off value between normal fasting glucose and IFG than
theWHO (5.6 mmol/l = 100 mg/dl vs. 6.1 mmol/l = 110 mg/dl)
[15]. Therefore we analyzed our data also using the ADA criteria.
The incidence of CFRD at the last OGTT was significantly higher
in the IFG, IGTwithout IFG, and the IGTwith IFG groups than in
the NGT group (Supplemental Table S1). The results of the
logistic regression analysis for IFG and IGT to predict future
CFRD confirm both as independent risk indicators similar to the
analysis using WHO guidelines (Supplemental Table S2). The
additional analyses using ADA criteria in the subsample of 509
patients also confirmed INDET as a risk indicator for future
CFRD (Supplemental Tables S3 and S4).Table 4
Change in glycemic control determined by oral glucose tolerance testing over 3.6 ± 2
were classified according to WHO guidelines. Patients with NGT were further divid
NGT
Glucose response at the first OGTT NGT No INDET n = 199
(74.0%)
n
(
INDET n = 66
(56.9%) (
IFG n = 21
(47.7%) (
IGT without IFG n = 41
(54.0%) (
IGT with IFG n = 6
(37.5%) (
Total n = 333
(63.9%)
n
(4. Discussion
This study evaluated the prognostic value of impaired fasting
glycemia, impaired glucose tolerance and indeterminate glycemia
based on OGTT with respect to future glucose tolerance in the
largest sample of patients with CF analyzed so far.
Impaired fasting glycemia was associated with a significantly
higher incidence of CFRD in the following 3.6 years compared
to the group with normal glucose tolerance. This finding is in line
with our hypothesis that impaired fasting glycemia is a predictor
for CFRD.
Our findings are in contrast to the results of Frohnert et al. [11]
who found no increased risk to develop CFRD in patients with
IFG. There are several possible explanations for the differences
among the studies: 1) The sample size in our study was about three
times larger than in that by Frohnert et al. [11] thereby allowing to
detect smaller effects. 2) Frohnert et al. [11] defined impaired
fasting glucose based on the American Diabetes Association
guidelines of 2003 at fasting glucose levels of 5.6–6.9 mmol/l
(100–125 mg/dl) while we included only patients with blood
glucose levels of 6.1–6.9 mmol/l (110–125 mg/dl), based on the.1 years in 521 patients with CF and no CF-related diabetes at first test. Patients
ed into those without INDET and those with INDET.
Glucose response to the last OGTT
IFG IGT without IFG IGT with IFG CFRD Total
= 16
6.0%)
n = 30
(11.2%)
n = 5
(1.9%)
n = 19
(7.1%)
n = 269
(51.6%)
n = 9
7.8%)
n = 18
(15.5%)
n = 3
(2.6%)
n = 20
(17.2%)
n = 116
(22.3%)
n = 4
9.1%)
n = 7
(15.9%)
n = 1
(2.3%)
n = 11
(25.0%)
n = 44
(8.5%)
n = 2
2.6%)
n = 16
(21.1%)
n = 0
(0.0%)
n = 17
(22.4%)
n = 76
(14.6%)
n = 0
0.0%)
n = 3
(18.8%)
n = 0
(0.0%)
n = 7
(43.8%)
n = 16
(3.1%)
= 31
6.0%)
n = 74
(14.2%)
n = 9
(1.7%)
n = 74
(14.2%)
n = 521
(100%)
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and confirmed by the WHO in 2006 [15]. Thus, by excluding
patients with fasting glucose levels of 5.6–6.0 mmol/l we selected
a group of patients as IFG who may be at a higher risk for future
CFRD compared to the group of Frohnert et al. [11]. 3) The
baseline mean age of 26 years in the study of Frohnert et al. [11],
was much higher than baseline age in our study (18 years).
Furthermore, the follow-up period was longer in the study by
Frohnert et al. [11] compared to our study (6.5 years vs. 3.6 years,
respectively). The higher age and/or the longer follow-up was
associated with a higher rate of CFRD development during the
study period in the reference NGT group described by Frohnert
et al. (27%) compared to our study (10%) which may have
hampered the detection of an effect of IFG on future CFRD. 4)
Furthermore, Frohnert et al. [11] evaluated the progression to
CFRD with fasting hyperglycemia (CFRD FH+) while patients
with CFRD without fasting hyperglycemia (CFRD FH-) were not
included in the analysis. This may have an impact on the result as
well.
With respect to the results of Frohnert et al. [11] we analyzed
our data additionally using ADA criteria. As expected, when
lowering the cut-off between normal fasting glucose and IFG
from 6.1 mmol/l (WHO) to 5.6 mmol/l (ADA), data showed a
significant increase in IFG prevalence (ADA: 19.7% vs. WHO
6.4% respectively). However, relatively fewer individuals with
IFG developed CFRD during the study period when applying
the ADA definition (15.6%) compared to the WHO definition
(24.3%). Anyhow, even when using ADA criteria, the progres-
sion from IFG to CFRD was significantly more common than
from NGT to CFRD (p = 0.04) and the logistic regression
analysis showed IFG as an independent risk factor for CFRD.
Thus, our study establishes IFG as an independent risk indicator
for developing CFRD regardless of the definition (WHO or ADA
criteria).
The prevalence of IGT at the first test (14.2%) in our study
was somewhat lower than that reported by others [7,11]. This
may be explained by a relatively low mean age in our study
population. IGT was a significant predictor for future CFRD in
our large sample. This finding is in line with other studies
[8–10] and with our hypothesis.
For the first time, we assessed the predictive value of IFG
and IGT for future CFRD relatively to each other. The analyses
showed that the two markers of impaired glycemic control were
independent of each other, as IFG and IGT without IFG were
both significant predictors of future CFRD. Furthermore, the
odds ratio for CFRD in people with IGT with IFG was about
double the odds ratio of IFG or IGT without IFG alone.
Additionally to theWHO categories for glucose tolerance based
on OGTT, we investigated the prognostic value of INDET in
patients with CF and NGT. The incidence of subsequent CFRD in
this subgroup was more than double compared to the group with
NGTwho had a normal glucose level one hour after a standardized
challenge. So far, the prognostic value of INDET with respect
to CFRD was not systematically assessed [3,4]. Our data thus
complement the findings of Ode et al. 2010 [10] who identified
INDET as a risk factor for future CFRD in prepubertal children
aged 6–9 years. Based on these results, it may be suggested tomeasure blood glucose levels one hour after an oral glucose load,
in addition to the baseline and the 2-hour level as currently
recommended [3,16]. This proposal would be in line with recent
propositions [4,13]. Furthermore, given the higher incidence in
CFRD in patients with IFG, IGT, or INDET, it may also be
considered to reduce the time interval between routine tests from
annually to every 6 months in patients with an increased risk for
future CFRD.
Glycemic control in cystic fibrosis usually deteriorates over
time but may fluctuate considerably in individuals. In fact,
Table 1 demonstrates that even patients with both IFG and IGT in
one OGTT may have a normal glucose tolerance in a subsequent
OGTT. Nevertheless, recent data suggest that an early detection of
abnormal glucose tolerance, respective education and nutritional
counseling slows the decline in FEV1 and nutritional status
otherwise common in these patients [10]. Thus, regular testing
for alterations in glycemic control is important in CF. Since
deterioration of clinical, pulmonary and nutritional status can
occur several years before diagnosis of CFRD [17,18], the role of
treating pre diabetes is receiving increasing attention [19,20]. The
currently recommended treatment of CFRD is insulin [3,4,16].
This study has some limitations. First, the number of patients
in some subgroups was relatively small. Furthermore, despite
stringent inclusion and exclusion criteria and a clear study
protocol, there might have been some differences in timing of
OGTT and test procedures among centers, which may have
added to the variation in test results. Last but not least, the
follow-up period between first and last OGTT varied among
patients which also may have confounded the results. However,
our sample is the largest investigated so far and we were able to
detect significantly increased risks for future CFRD in all groups
with an abnormal OGTT result.
In conclusion, analyzing blood glucose levels using the
WHO and the ADA guidelines identified INDET, IFG, IGT
without IFG, and IGT with IFG as predictors for future CFRD.
Since the WHO definition of IFG seems to allow a stronger
prediction of future CFRD, we would suggest using the WHO
criteria for this purpose.
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